8-K: Windtree Therapeutics Offers Reduced Conversion Price for Series C Preferred Stock

Windtree Therapeutics is offering holders of its Series C Convertible Preferred Stock a reduced conversion price of $0.1608 in exchange for agreeing to certain forbearance terms.

Summary

• Windtree Therapeutics has offered to reduce the conversion price of its Series C Convertible Preferred Stock to $0.1608 per share.
• This offer is contingent on holders agreeing to certain forbearance terms, which include refraining from exercising default remedies until April 30, 2025.
• The forbearance applies to breaches under the Securities Purchase Agreements, Warrants, Registration Rights Agreements, and other related transaction documents.
• Holders must sign and return the conversion notice by 5:00 p.m. Eastern Time on January 31, 2025, to accept the offer.
• There is no guarantee that all holders will accept the offer.
• The company has previously registered the resale of up to 27,668,106 shares of common stock issuable upon conversion of the Series C Preferred Stock and exercise of warrants.

Sentiment

Score: 6

Explanation: The document outlines a strategic move to manage the company's capital structure, which is neither overly positive nor negative. The success of the offer is uncertain, but the company is taking steps to address potential issues.

Positives

• The reduced conversion price may be attractive to holders of the Series C Preferred Stock.
• The forbearance terms provide the company with a period of stability regarding potential defaults until April 30, 2025.
• The company has already registered a significant number of shares for resale related to the conversion and warrants.

Negatives

• There is no guarantee that all holders of the Series C Preferred Stock will accept the offer.
• The forbearance terms may limit the rights of the holders until April 30, 2025.

Risks

• If a significant number of holders do not accept the offer, the company may not achieve its desired outcome.
• The forbearance terms could potentially lead to future disputes if not managed carefully.
• The company is reliant on the conversion of the preferred stock to raise capital.

Future Outlook

The company is seeking to convert Series C Preferred Stock to common stock at a reduced price, which could impact the company's capital structure and future financing options. The success of this offer is dependent on the acceptance of the holders.

Management Comments

• The company has decided to offer to reduce the Conversion Price as defined in the Series C Certificate of Designation of each share of Series C Preferred Stock to $0.1608.

Industry Context

This type of transaction is not uncommon for companies seeking to manage their capital structure and reduce potential liabilities. It is often used to incentivize investors to convert preferred stock to common stock, which can simplify the company's balance sheet.

Comparison to Industry Standards

• Similar transactions are often seen in the biotech industry, where companies frequently use convertible preferred stock to raise capital.
• The specific terms of the conversion and forbearance are unique to Windtree Therapeutics, but the general strategy is consistent with industry practices.
• Other companies such as Athersys and Ocugen have used similar strategies to manage their capital structure, although the specific terms and conditions vary.

Stakeholder Impact

• Shareholders may see a change in the number of outstanding shares if the conversion is successful.
• Holders of Series C Preferred Stock will need to decide whether to accept the offer.
• The company's financial stability may be improved by the conversion and forbearance.

Next Steps

• Holders of Series C Preferred Stock must decide whether to accept the reduced conversion price offer by January 31, 2025.
• The company will issue common stock to holders who accept the offer.
• The company will monitor the impact of the conversion on its capital structure.

Key Dates

Keywords

Series C Convertible Preferred Stock, Conversion Price, Forbearance, Securities Purchase Agreements, Warrants, Registration Rights Agreements, Common Stock, Windtree Therapeutics